We are delighted at Panacea to announce that Linda Barducci has recently joined our team as Head of Pharmacovigilance. She has an extensive pharmacovigilance background, having worked in this area for the last 14 years. Linda has covered all aspects of pharmacovigilance in some of the top 10 pharma companies as well as for a leading CRO. In addition to specialising in post-marketing pharmacovigilance, she has an extensive background in global clinical trials (Phase I-III) and has also worked on investigator-led studies and Phase IV post-authorisation safety studies. Linda has worked with medicinal products, vaccines, medical devices and OTC products.
Therapeutic areas covered include oncology, cardiology, metabolic disorders, neuroscience, ophthalmology, transplant medicine, in¬ammatory disorders, respiratory disorders, infectious diseases including HIV, tuberculosisis and hepatitis C, endocrinology, dermatology, gynaecology, psychiatry, gastroenterology, urology, orthopaedics, paediatrics, neonatal medicine and facial aesthetics. During her pharmacovigilance career, Linda has taken a leading role in numerous internal audits and inspections run by the EMA, MHRA, FDA, AIFA, Health Canada and SwissMedic. Furthermore, since 2010 Linda has been undertaking the role of global PV trainer. Prior to her pharmacovigilance career, and following the successful completion of her Diploma in Medical Administration, Linda worked in various London hospitals and medical research institutes before going on to edit two medical journals and various medical textbooks. She has experience in running both national and international medical associations and organising national and international medical meetings.
Linda can be contacted on +44 1624 672777 or by e-mail at email@example.com